OBJECTIVE： To systematically review the effectiveness and safety of haloperidol in the prevention of nausea and vomiting （PONV）， and provide evidence-based reference for off-label drug use in clinic. METHODS： Retrieved from Medline （PubMed）， Embase （Ovid）， Cochrane Library， Clinical trials， CBM， CNKI， VIP and Wanfang Database， randomized controlled trials （RCT） about the haloperidol alone or combined with conventional antiemetic regimens versus positive drugs or placebo or conventional antiemetic regimens in the prevention of PONV were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation by modified Jadad scale. RESULTS： Totally 15 RCTs were included， involving 2 629 patients. Results of Meta-analysis showed， compared with placebo， haloperidol can significantly improve the control rate of PONV within 24 h [RR＝1.69，95％CI（1.35， 2.12），P＜0.001]， while compared with ondansetron/tropisetron， there was no significant difference [24 h：RR＝1.00，95％CI（0.89，1.12），P＝0.99]； compared with conventional antiemetic regimens， haloperidol combined with conventional antiemetic regimens can significantly improve 24 h [RR＝1.21，95％CI（1.06，1.39），P＝0.006] and 48 h [OR＝7.58，95％CI（3.59，16.02），P＜0.001] control rate of PONV. And there were no significant differences in the incidences of extrapyramidal reactions [RR＝3.05，95％CI（0.74，12.67），P＝0.12]， sedation [RR＝1.27，95％CI（0.73，2.20），P＝0.39] and Q-T interval prolongation [RR＝1.06，95％CI（0.77，1.48），P＝0.71] in 2 groups. CONCLUSIONS： Haloperidol can effectively prevent the nausea and vomiting induced by surgeries， and shows good effects on the PONV within 24 h and 48 h， do not increase the incidences of extrapyramidal reactions， sedation and adverse reactions in Q-T interval prolongation..